You can buy Lucirevu at the lowest price in the online pharmacy Nextgen.ooo . Revumenib is a small molecule menin inhibitor for the treatment of relapsed/refractory leukemia with KMT2A translocation. Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in the majority of infant acute lymphoblastic leukemia cases. Aberrant KMT2A is associated with the upregulation of leukemogenic transcription pathways, notably those involving HOXA genes and their co-factor MEIS1. Menin is a scaffold protein that interacts with both the wild-type and rearranged KMT2A, which is crucial for KMT2A activity and the maintenance of HOXA expression and leukemogenesis.
 
Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations, becoming the first menin inhibitor to receive FDA approval. In October of 2025, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations.